2022-04-11 16:00Financial Performance - The company's audited revenue decreased by 62.97 million yuan compared to the preliminary report, representing a nearly 1% reduction due to adjustments made by auditors based on revenue cutoff differences[6]. - The company reported a total revenue of RMB 1.5 billion for the fiscal year 2021, representing a year-over-year increase of 15%[22]. - The company's operating revenue for 2021 was ¥6,365,177,483.41, an increase of 19.38% compared to ¥5,332,074,875.27 in 2020[34]. - The net profit attributable to shareholders for 2021 was ¥240,787,578.67, a decrease of 76.49% from ¥1,024,209,839.93 in 2020[34]. - The net profit after deducting non-recurring gains and losses was ¥90,112,059.27, down 84.78% from ¥592,007,482.48 in 2020[34]. - The net cash flow from operating activities was -¥6,629,319.80, a decline of 117.78% compared to ¥37,283,625.07 in 2020[34]. - The total operating revenue for 2021 was approximately ¥6.37 billion, representing a year-over-year increase of 19.38% from ¥5.33 billion in 2020[91]. - The pharmaceutical manufacturing sector accounted for ¥6.36 billion, or 99.98% of total revenue, with a year-over-year growth of 19.38%[91]. - The company's international revenue reached approximately ¥5.81 billion, accounting for 91.24% of total revenue, with a growth of 20.96% year-over-year[91]. Investment and R&D - The company is investing RMB 200 million in R&D for new drug development, focusing on innovative therapies for rare diseases[22]. - The company’s R&D expenses increased by 38.18% year-on-year, totaling ¥221.10 million in 2021, primarily due to increased investment in R&D projects[108]. - The number of R&D personnel increased to 332 in 2021, up 13.70% from 292 in 2020[111]. - R&D investment amounted to ¥245,824,660.32 in 2021, representing a 49.90% increase from ¥163,994,431.96 in 2020[111]. - The company has increased investment in new drug development, establishing a pipeline of innovative drugs in various clinical stages[175]. Market Expansion and Strategy - Future guidance estimates a revenue growth of 10-15% for the next fiscal year, driven by new product launches and market expansion efforts[22]. - Market expansion efforts include entering two new countries in Europe, aiming for a 5% market share within the first year of operation[22]. - The company is focusing on strategic partnerships with international firms to leverage their distribution networks and increase market penetration[22]. - The company plans to enhance its CDMO services, targeting a 25% increase in contract manufacturing revenue over the next two years[22]. - The company aims to enhance its sales and marketing network in the EU and other global markets, including China, to improve development and production capabilities[155]. Challenges and Risks - The company faced challenges in the audit process due to the pandemic, affecting the collection and preparation of necessary documents[6]. - The company highlighted that the main factors causing discrepancies in net profit were related to investment income losses and impairment of investment project-related assets, which are not related to core business operations[9]. - The company faces risks including product quality, market competition, and reliance on core products, which could adversely affect revenue and profitability[171][172][173]. - The company acknowledges potential adverse effects from outbreaks of infectious diseases on its supply chain and overall business operations[179]. Corporate Governance - The company has established a complete independent business system, ensuring independence in operations, personnel, assets, and finance from its controlling shareholder[191]. - The board of directors consists of 7 members, including 3 independent directors, meeting the legal requirements[186]. - The company strictly adheres to information disclosure regulations, ensuring transparency and fairness in communication with investors[189]. - There were no incidents of the controlling shareholder interfering in the company's operations or decision-making during the reporting period[185]. - The company has maintained a robust internal control system to ensure compliance with relevant laws and regulations[185]. Shareholder Engagement - The company held an earnings conference call on April 28, 2021, to discuss its financial performance with institutional investors[181]. - The annual shareholder meeting on May 26, 2021, had a participation rate of 68.18%[194]. - The first extraordinary shareholder meeting on September 28, 2021, had a participation rate of 69.17%[194].